Bridging the gap between science and business

ABOUT

Dr. Peter French is a leader in the Australian biotechnology industry with more than 40 years’ experience in both academic and commercial executive roles in the life sciences industry. 

Dr French brings his rare combination of academic and commercial experience to each project. Not only can he do a deep dive into the science to examine the strengths and weaknesses of a potential technology, but he can also review the potential commerciality of the organisation’s business case.

 

His qualifications and work experience over the past 40 years support this duality of expertise. He holds both a PhD in cell and molecular biology and an MBA in Technology Management. He has conducted research in a range of fields including neuroscience, cell biology of cancer, immunology and inflammation, infectious disease, diagnostic assay development, in vitro imaging, gene therapy and clinical trials. 

 

In the biotechnology industry, he has founded or co-founded several ASX-listed and private companies, and has listed one company on the NASDAQ. He has raised around $100M in funding from US and Australian investors to support the development of early stage Australian life sciences companies. He is an experienced Director, having served on several public company Boards in Australia.

 

SERVICES

DUE DILIGENCE

On the science or technology under consideration.

NETWORKING

Utilising my extensive Australian biotechnology and healthcare network to connect organisations

FUND RAISING

Advice on capital raising approaches in the US and Australia

MENTORING

Advice and assistance for early and mid-career professionals in the life sciences field.

ARTICLES

COMMERCIALISING MEDTECH –

HOW TO IMPROVE YOUR CHANCES OF SUCCESS

JUNE 2020

“It has been estimated that the Australian MedTech industry grosses over ten billion dollars annually. This is attributed to the relatively small number of companies that are successful in commercialising their products in comparison to all companies that start with a bright idea. Many, possibly as many as 90% of innovations, will fail. 

This paper examines some of the most common reasons for this failure, and suggests some strategies to increase your chances of success in this complex and rewarding field…”

 
 
sienna cancer diagnosticas.png
bard-logo.png
logo@2x.png
logo_white_edited.jpg

CLIENTS